TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1268617
Drug: Prolonged methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged methyldopa treatment (mean 13.4 months)
Study: 28747208
Drug: Obinutuzumab (GA-101)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (GA-101) consolidation therapy
Study: 28747208
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (standard care)
Study: 21222131
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA (600 mg EPA and 400 mg DHA per day)
Study: 21222131
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA (600 mg EPA and 400 mg DHA per day) + antioxidants (30 mg vitamin E, 60 mg vitamin C, 6 mg β-carotene)
Study: 17854246
Drug: Risperidone long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long‐acting injection (25 mg, 37.5 mg, or 50 mg every 2 weeks)
Study: 17854246
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone (4 mg/day or less, 4-6 mg/day, or more than 6 mg/day)
Study: 17854246
Drug: Risperidone long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long‐acting injection (25 mg or 37.5 mg every 2 weeks)
Study: 15701857
Drug: PemOx (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PemOx (pemetrexed 500 mg/m² plus oxaliplatin 120 mg/m²)
Study: 11892854
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a brochure and videotape
Study: 11892854
Drug: Preparation procedures
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation procedures
Study: 9535247
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg DTPwHB vaccine
Study: 9535247
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg DTPwHB vaccine
Study: 7805711
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg once a day (n = 10)
Study: 7805711
Drug: Permixon 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permixon 80 mg x 2 twice a day (n = 11)
Study: 2683535
Drug: 1-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day treatment with metronidazole and ampicillin
Study: 2683535
Drug: 4-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-day treatment with metronidazole and ampicillin
Study: 28776894
Drug: 75 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg/kg initial dose of activated eptacog beta (rhFVIIa)
Study: 28776894
Drug: 225 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 μg/kg initial dose of activated eptacog beta (rhFVIIa)
Study: 25015548
Drug: Nasal insufflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal insufflation (NI) therapy
Study: 15562200
Drug: LAF237 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAF237 (50 mg once daily, n=56)
Study: 15562200
Drug: LAF237 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAF237 (50 mg once daily, n=42)
Study: 6991095
Drug: 5-fluorouracil (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (IV 5‐FU) alone, 15 mg/kg/week
Study: 6991095
Drug: Combination therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy: cyclophosphamide (15 mg/kg/week IV on day 1) plus 5-fluorouracil (15 mg/kg/week IV during weeks 2‐5)
Study: 6991095
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (5-FU alone and combination therapy)
Study: 17762738
Drug: Embolization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolization treatment for DAVFs
Study: 9512283
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG‐ELS
Study: 9512283
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG‐ELS plus 296 mL magnesium citrate 1 hour prior
Study: 9512283
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG‐ELS plus bisacodyl 20 mg
Study: 7999653
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + F group (n = 27) - 38 mL of 1.5% lidocaine with 1/200,000 epinephrine and 100 micrograms of fentanyl
Study: 7999653
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + S group (n = 26) - 38 mL of 1.5% lidocaine with 1:200,000 epinephrine and 2 mL of normal saline
Study: 29945780
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg + 10 g Cr monohydrate (n = 10)
Study: 29945780
Drug: Placebo (atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (atorvastatin 80 mg + PL, n = 9)
Study: 11230288
Drug: Endothelium-dependent vasodilatation
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelium-dependent vasodilatation with acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg. 100 mL(‐1). min(‐1))
Study: 11230288
Drug: Endothelium-independent vasodilatation
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelium-independent vasodilatation with sodium nitroprusside (1, 2, and 4 microg. 100 mL(‐1). min(‐1))
Study: 9225641
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive with 20 micrograms ethinyl estradiol (EE)
Study: 9225641
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive with 30 micrograms ethinyl estradiol (EE)
Study: 2889391
Drug: Intranasal nitroglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nitroglycerine 0.75 mg
Study: 2889391
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution of saline (Control)
Study: 27852230
Drug: Dexamethasone 16
Normalized name: dexamethasone 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 16 mg IV preoperatively
Study: 24126567
Drug: ACT-280778 single
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-280778 single doses of 2, 5, 15, or 40 mg
Study: 24126567
Drug: ACT-280778 single
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-280778 single dose of 40 mg
Study: 24126567
Drug: ACT-280778 once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-280778 once-daily doses of 5 or 15 mg for 7 days
Study: 23965227
Drug: Decision aids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aids (DAs) for coronary prevention and diabetes medications
Study: 20627902
Drug: Stemless poly‐L/D‐lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stemless poly‐L/D‐lactide copolymer 96 : 4 (PLDLA) implant
Study: 20627902
Drug: Swanson silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swanson silicone implant
Study: 8905360
Drug: Flumazenil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.2 mg incrementally after procedure
Study: 6311692
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg bd
Study: 6311692
Drug: cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 300 mg nocte
Study: 6311692
Drug: twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily ranitidine
Study: 6311692
Drug: twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily cimetidine
Study: 30582753
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg of sublingual misoprostol
Study: 21971319
Drug: Milrinone, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone, 0.5 µg/kg/min during hypothermic cardiopulmonary bypass
Study: 12629464
Drug: HMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (3 g/d)
Study: 14981122
Drug: DCMs stored
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DCMs stored with proteolytic enzyme inhibitors or mineral oil
Study: 3793849
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg testosterone membrane
Study: 3793849
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg testosterone membrane
Study: 3793849
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg testosterone membrane
Study: 24952855
Drug: CYP2C19 genotype-guided
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotype-guided antiplatelet therapy (clopidogrel for *1/*1 patients, ticagrelor or prasugrel for *2 or *3 allele carriers)
Study: 24952855
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with ticagrelor or prasugrel
Study: 24952855
Drug: CYP2C19 genotype-guided
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotype-guided antiplatelet therapy
Study: 22540993
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist with a long-term protocol
Study: 22540993
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist with a multi-dose protocol
Study: 19481812
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (40 mg in 1 ml)
Study: 15334625
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg metformin
Study: 15334625
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg metformin
Study: 15334625
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg metformin
Study: 15334625
Drug: 2500 mg
Normalized name: inulin 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 mg metformin
Study: 23856771
Drug: GSK2336805 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2336805 (150 mg single dose)
Study: 21286910
Drug: Resection suspension
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection suspension arthroplasty according to Epping
Study: 19150702
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment with antacid, H2-receptor antagonist, and proton pump inhibitor (n=341)
Study: 19150702
Drug: Step-down treatment
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down treatment with proton pump inhibitor, H2-receptor antagonist, and antacid (n=323)
Study: 19150702
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment (n=341)
Study: 19150702
Drug: Step-down treatment
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down treatment (n=323)
Study: 15119993
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg levofloxacin for 5 days
Study: 15119993
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg levofloxacin for 10 days
Study: 9566995
Drug: Full-fat rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-fat rice bran (84 g/d)
Study: 9566995
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (84 g/d)
Study: 1698846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of basophil, antigen, histamine, and codeine skin sensitivity and reactivity
Study: 1273734
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of oral PGE2 given hourly
Study: 1273734
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of oral PGE2 hourly, starting with 0.5 mg and increasing to a maximum of 2.0 mg
Study: 1273734
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens of oral PGE2
Study: 28188965
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (ZS) 220-mg capsules (50 mg elemental zinc) from the 16th day of the menstrual cycle to the second day of the next cycle
Study: 16796081
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment group (n=35)
Study: 12489980
Drug: Lacidipine 8
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 8 mg (single dose)
Study: 12489980
Drug: Lacidipine (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (repeated doses of 2-6 mg)
Study: 12489980
Drug: Lacidipine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (single and repeated doses)
Study: 6184780
Drug: Alpha-amylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-amylase inhibitor
Study: 27927064
Drug: Yingliu mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yingliu mixture combined with methimazole (Y-M), orally administered 25 mL three times daily for 12 weeks.
Study: 27927064
Drug: Methimazole alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole alone, administered at 5-25 mg/day for 12 weeks.
Study: 24460309
Drug: Microwave hyperthermia
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave hyperthermia combined with cisplatin chemotherapy and radiotherapy
Study: 24460309
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cisplatin chemotherapy and radiotherapy only)
Study: 22263332
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (P2)
Study: 22263332
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone (P1)
Study: 10929034
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (ROAD-IN) consisting of ranimustine, vincristine, melphalan, dexamethasone, and interferon alpha (IFN-alpha) administered three times weekly for 3 weeks starting on day 22, repeated for three cycles.
Study: 10929034
Drug: Responders (CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders (CR + PR) to induction therapy.
Study: 10929034
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN-alpha) maintenance therapy.
Study: 10929034
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to induction therapy.
Study: 1458672
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (400 mg/kg by i.v. infusion over 3 h)
Study: 1458672
Drug: Placebo (albumen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (albumen and sucrose by similar infusion)
Study: 1458672
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin and Placebo
Study: 27548794
Drug: Caffeine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 1.5 mg·kg
Study: 27548794
Drug: Caffeine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3.0 mg·kg
Study: 27548794
Drug: Caffeine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6.0 mg·kg
Study: 27548794
Drug: Caffeine 7.5
Normalized name: codeine phosphate/butalbital/aspirin/caffeine 7.5 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 7.5 mg·kg
Study: 24586912
Drug: RUTI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTI vaccine (25 µg)
Study: 24586912
Drug: RUTI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTI vaccine (5 µg)
Study: 24586912
Drug: RUTI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTI vaccine (50 µg)
Study: 21719717
Drug: ONO-5334 600
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 600 mg once daily
Study: 21719717
Drug: ONO-5334 100
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 100 mg
Study: 21719717
Drug: ONO-5334 300
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 300 mg and 600 mg
Study: 21719717
Drug: ONO-5334 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 (various doses)
Study: 19926400
Drug: Naltrexone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (32 mg/day) and bupropion (360 mg/day) plus behavioral counseling
Study: 16930857
Drug: Tiagabine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 24 mg/day
Study: 16231757
Drug: Strict treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict treatment to maintain systolic BP below 140 mmHg (group A)
Study: 16231757
Drug: Mild treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild treatment to maintain systolic BP between 140 and below 160 mmHg (group B)
Study: 11973014
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration with painful stimulation
Study: 11973014
Drug: Verbal expectancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal expectancy for drug efficacy and individual differences in suggestibility
Study: 11973014
Drug: Concurrent pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent pain intensity and unpleasantness
Study: 9989684
Drug: Test supplement
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test supplement (wheat fiber and protein)
Study: 9989684
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (American Association of Cereal Chemists wheat bran supplement)
Study: 9989684
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (1.7 g fiber/d)
Study: 2258026
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) at dosage of 15 mg/kg/daily
Study: 2258026
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at dosage of 15 mg/kg/daily
Study: 21501336
Drug: 40mg oral
Normalized name: Iron 40mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg oral baclofen
Study: 18984660
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IGF‐I injections
Study: 17303495
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg plus sublingual misoprostol 600 microg before D&E
Study: 17303495
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg plus vaginal misoprostol 600 microg before D&E
Study: 17303495
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 600 microg before D&E
Study: 11796079
Drug: 8 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 sessions of group music therapy
Study: 11796079
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no group music therapy)
Study: 9401647
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading
Study: 8017669
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with hyperbaric bupivacaine 0.5% (0.08 mg.cm‐1 of height)
Study: 8017669
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with a bolus dose of 0.5% plain bupivacaine followed by continuous infusion
Study: 27570089
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg oral daily
Study: 22104960
Drug: 80 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp with MC‐CM (70 mL of 300 mgI/mL)
Study: 22104960
Drug: 120 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 kVp with HC‐CM (70 mL of 370 mg iodine/mL)
Study: 18457338
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance Interpersonal Psychotherapy (IPT)
Study: 10491544
Drug: Multiple-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-agent chemotherapy and irradiation to the primary tumor volume
Study: 10491544
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone injections
Study: 8946439
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg and placebo (Group I, n = 13)